PSB-0739 sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530557

CAS#: 1052087-90-7

Description: PSB-0739 is an extremely potent and selective competitive P2Y12 receptor antagonist (pA2 of 9.8).

Chemical Structure

PSB-0739 sodium
CAS# 1052087-90-7

Theoretical Analysis

MedKoo Cat#: 530557
Name: PSB-0739 sodium
CAS#: 1052087-90-7
Chemical Formula: C26H17N3Na2O8S2
Exact Mass: 0.00
Molecular Weight: 609.535
Elemental Analysis: C, 51.23; H, 2.81; N, 6.89; Na, 7.54; O, 21.00; S, 10.52

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: PSB-0739; PSB 0739; PSB0739 sodium

IUPAC/Chemical Name: 1-Amino-9,10-dihydro-9,10-dioxo-4-[[4-(phenylamino)-3-sulfophenyl]amino]-2-anthracenesulfonic acid sodium salt


InChi Code: InChI=1S/C26H19N3O8S2.2Na/c27-24-21(39(35,36)37)13-19(22-23(24)26(31)17-9-5-4-8-16(17)25(22)30)29-15-10-11-18(20(12-15)38(32,33)34)28-14-6-2-1-3-7-14;;/h1-13,28-29H,27H2,(H,32,33,34)(H,35,36,37);;/q;2*+1/p-2

SMILES Code: O=S(C(C(N)=C1C2=O)=CC(NC3=CC=C(NC4=CC=CC=C4)C(S(=O)([O-])=O)=C3)=C1C(C5=C2C=CC=C5)=O)([O-])=O.[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 609.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Bekő K, Koványi B, Gölöncsér F, Horváth G, Dénes Á, Környei Z, Botz B, Helyes Z, Müller CE, Sperlágh B. Contribution of platelet P2Y(12) receptors to chronic Complete Freund's adjuvant-induced inflammatory pain. J Thromb Haemost. 2017 Mar 27. doi: 10.1111/jth.13684. [Epub ahead of print] PubMed PMID: 28345287.

2: Giacomazzi A, Degan M, Calabria S, Meneguzzi A, Minuz P. Antiplatelet Agents Inhibit the Generation of Platelet-Derived Microparticles. Front Pharmacol. 2016 Sep 16;7:314. eCollection 2016 Sep 16. PubMed PMID: 27695417; PubMed Central PMCID: PMC5025445.

3: Kishore BK, Carlson NG, Ecelbarger CM, Kohan DE, Müller CE, Nelson RD, Peti-Peterdi J, Zhang Y. Targeting renal purinergic signalling for the treatment of lithium-induced nephrogenic diabetes insipidus. Acta Physiol (Oxf). 2015 Jun;214(2):176-88. doi: 10.1111/apha.12507. Epub 2015 May 4. Review. PubMed PMID: 25877068; PubMed Central PMCID: PMC4430398.

4: Zhang Y, Peti-Peterdi J, Müller CE, Carlson NG, Baqi Y, Strasburg DL, Heiney KM, Villanueva K, Kohan DE, Kishore BK. P2Y12 Receptor Localizes in the Renal Collecting Duct and Its Blockade Augments Arginine Vasopressin Action and Alleviates Nephrogenic Diabetes Insipidus. J Am Soc Nephrol. 2015 Dec;26(12):2978-87. doi: 10.1681/ASN.2014010118. Epub 2015 Apr 8. PubMed PMID: 25855780; PubMed Central PMCID: PMC4657822.

5: Horváth G, Gölöncsér F, Csölle C, Király K, Andó RD, Baranyi M, Koványi B, Máté Z, Hoffmann K, Algaier I, Baqi Y, Müller CE, Von Kügelgen I, Sperlágh B. Central P2Y12 receptor blockade alleviates inflammatory and neuropathic pain and cytokine production in rodents. Neurobiol Dis. 2014 Oct;70:162-78. doi: 10.1016/j.nbd.2014.06.011. Epub 2014 Jun 25. PubMed PMID: 24971933; PubMed Central PMCID: PMC4148180.

6: Deflorian F, Jacobson KA. Comparison of three GPCR structural templates for modeling of the P2Y12 nucleotide receptor. J Comput Aided Mol Des. 2011 Apr;25(4):329-38. doi: 10.1007/s10822-011-9423-3. Epub 2011 Apr 3. PubMed PMID: 21461952; PubMed Central PMCID: PMC3157290.

7: Hoffmann K, Baqi Y, Morena MS, Glänzel M, Müller CE, von Kügelgen I. Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J Pharmacol Exp Ther. 2009 Nov;331(2):648-55. doi: 10.1124/jpet.109.156687. Epub 2009 Aug 18. PubMed PMID: 19690189.

8: Baqi Y, Atzler K, Köse M, Glänzel M, Müller CE. High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem. 2009 Jun 25;52(12):3784-93. doi: 10.1021/jm9003297. PubMed PMID: 19463000.